These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18590614)

  • 1. Neuroprotection in Parkinson's disease: myth or reality?
    Voss T; Ravina B
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues in neuroprotection clinical trials in Parkinson's disease.
    Kieburtz K
    Neurology; 2006 May; 66(10 Suppl 4):S50-7. PubMed ID: 16717252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial designs used to study neuroprotective therapy in Parkinson's disease.
    Lang AE; Melamed E; Poewe W; Rascol O
    Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
    Hung AY; Schwarzschild MA
    Curr Opin Neurol; 2007 Aug; 20(4):477-83. PubMed ID: 17620885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
    de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V
    Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurobiology and treatment of Parkinson's disease.
    Schapira AH
    Trends Pharmacol Sci; 2009 Jan; 30(1):41-7. PubMed ID: 19042040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A responsive outcome for Parkinson's disease neuroprotection futility studies.
    Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K;
    Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for trials of neuroprotection in Parkinson's disease.
    Agarwal PA; Stoessl AJ
    Mov Disord; 2013 Jan; 28(1):71-85. PubMed ID: 22927101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson's Disease?
    Ong WY; Leow DM; Herr DR; Yeo CJ
    Neuromolecular Med; 2023 Mar; 25(1):1-13. PubMed ID: 35776238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET.
    Brooks DJ
    J Neural Transm Suppl; 2000; (60):125-37. PubMed ID: 11205135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concerning neuroprotective therapy for Parkinson's disease.
    Uitti RJ; Wszolek ZK
    J Neural Transm Suppl; 2006; (70):433-7. PubMed ID: 17017564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in Parkinson's disease.
    Gillies GE; Pienaar IS; Vohra S; Qamhawi Z
    Front Neuroendocrinol; 2014 Aug; 35(3):370-84. PubMed ID: 24607323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials aimed at detecting neuroprotection in Parkinson's disease.
    Hauser RA; Zesiewicz TA
    Neurology; 2006 May; 66(10 Suppl 4):S58-68. PubMed ID: 16717253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.